Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Glioblastoma vs temozolomide: can the red queen race be won?

Arora A, Somasundaram K.

Cancer Biol Ther. 2019;20(8):1083-1090. doi: 10.1080/15384047.2019.1599662. Epub 2019 May 8.

PMID:
31068075
2.

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.

Gil Del Alcazar CR, Todorova PK, Habib AA, Mukherjee B, Burma S.

Mol Cancer Res. 2016 Oct;14(10):928-940. Epub 2016 Jun 29.

3.

20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.

Chen Z, Wei X, Shen L, Zhu H, Zheng X.

Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.

4.

Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr.

J Neurooncol. 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28.

PMID:
26311249
5.

Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?

Tanaka S, Akimoto J, Narita Y, Oka H, Tashiro T.

J Neurosurg. 2014 Oct;121(4):818-26. doi: 10.3171/2014.6.JNS132535. Epub 2014 Aug 8.

PMID:
25105699
6.

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M.

Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Review.

7.

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.

Yoshimoto K, Mizoguchi M, Hata N, Murata H, Hatae R, Amano T, Nakamizo A, Sasaki T.

Front Oncol. 2012 Dec 5;2:186. doi: 10.3389/fonc.2012.00186. eCollection 2012.

8.

Temozolomide resistance in glioblastoma multiforme.

Lee SY.

Genes Dis. 2016 May 11;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. eCollection 2016 Sep. Review.

9.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
10.

Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.

Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW.

Cancer Res. 2011 Mar 15;71(6):2308-17. doi: 10.1158/0008-5472.CAN-10-3213.

11.

NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.

Cho HY, Wang W, Jhaveri N, Lee DJ, Sharma N, Dubeau L, Schönthal AH, Hofman FM, Chen TC.

Mol Cancer Ther. 2014 Aug;13(8):2004-17. doi: 10.1158/1535-7163.MCT-13-0964. Epub 2014 Jul 3.

12.

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.

Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD.

Oncology. 2010;78(2):103-14. doi: 10.1159/000306139. Epub 2010 Mar 31.

PMID:
20357518
13.

STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.

Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S.

Mol Cancer Ther. 2012 Jun;11(6):1289-99. doi: 10.1158/1535-7163.MCT-11-0801. Epub 2012 Apr 24.

14.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

15.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

16.

Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.

Bobola MS, Kolstoe DD, Blank A, Silber JR.

Mol Cancer Ther. 2010 May;9(5):1208-18. doi: 10.1158/1535-7163.MCT-10-0010.

17.

The strategy for enhancing temozolomide against malignant glioma.

Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J.

Front Oncol. 2012 Aug 14;2:98. doi: 10.3389/fonc.2012.00098. eCollection 2012.

18.

Therapy and progression--induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme.

Agarwal S, Suri V, Sharma MC, Sarkar C.

Indian J Cancer. 2015 Oct-Dec;52(4):568-73. doi: 10.4103/0019-509X.178403. Review.

19.

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.

McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD.

Cancer Res. 2015 Aug 1;75(15):3127-38. doi: 10.1158/0008-5472.CAN-14-3616. Epub 2015 May 29.

20.

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmström A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, Berger MS, Söderkvist P, Taylor BS, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF.

Acta Neuropathol. 2015 Apr;129(4):597-607. doi: 10.1007/s00401-015-1403-6. Epub 2015 Feb 28.

Supplemental Content

Support Center